Market research
EVE.AU EVE Investments Limited
AU AUD Consumer Defensive
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.4
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- ISIN
- AU000000EVE3
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.4
About
About EVE Investments Limited
EVE Health Group Limited, a life sciences and healthcare company, engages in the development and commercialization of pharmaceutical products in Australia. It operates in two segments, Meluka (Branded Wellness Consumer Products) and Nextract (Pharmaceutical Products and Intellectual Property). Its lead product is the Dyspro, a formulation developed to address dysmenorrhoea and Endometriosis Pain; and Libbo, an oral dissolving film for erectile dysfunction. The company also develops Apixaban to treat anticoagulation. The company was formerly known as EVE Investments Limited. EVE Health Group Limited was incorporated in 2003 and is based in Subiaco, Australia.
Research context
EVE Investments Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the EVE.AU discussion.
5 years, 6 months ago
EVE Investments Limited is currently in a long term downtrend where the price is trading 48.3% below its 200 day moving average.
From a valuation standpoint, the stock is 88.7% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 6.0.
EVE Investments Limited's total revenue rose by 164.9% to $2M since the same quarter in the previous year.
Its net income has increased by 19.3% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 45.9% to $-379K since the same quarter in the previous year.
Based on the above factors, EVE Investments Limited gets an overall score of 4/5.